Enhancing Neonatal Intensive Care With Rapid Genome Sequencing
Shan Jiang,Bonny Parkinson,Yuanyuan Gu
DOI: https://doi.org/10.1001/jamanetworkopen.2024.0097
2024-02-23
JAMA Network Open
Abstract:Early diagnosis through genome sequencing can significantly transform clinical care for critically ill neonates. Traditional testing methods often fall short in accurately diagnosing genetic conditions due to overlapping symptoms in this age group. Genome sequencing, on the other hand, has proven more effective and has been used in various contexts for identifying hereditary conditions. The recent study by Marom et al 1 highlights the practicality and benefits of rapid trio genome sequencing (rtGS) in neonatal intensive care units (NICUs) in Israel. This study, involving medical genetics institutes and NICUs across the country, managed a rapid report turnaround of just 7 days, covering 130 neonates with suspected genetic disorders. The study's findings 1 are quite significant. The rtGS technology identified various genetic conditions, including 12 chromosomal disorders, 52 monogenic disorders, and a range of variants of unknown significance (VUSs). Notably, these findings led to changes in medical management for 22% of the neonates (24 of 107). Results led to immediate precision medicine for 6 diagnosed infants and palliative care for 2 other infants. This demonstrates the effectiveness of rtGS in a public health care setting, suggesting its potential for wider adoption in routine neonatal care. The introduction of rtGS in neonatal intensive care represents a significant advancement, particularly in searching for pathogenic and pharmacogenomic variants. This technology empowers health care practitioners to apply precision medicine strategies, tailored to the genetic profiles of individual patients. Early identification of genetic disorders through rtGS enables timely and targeted interventions, markedly improving patient outcomes. The capability to diagnose and intervene at an early stage is a significant leap forward in neonatal intensive care, emphasizing the crucial role of rtGS in modern health care practices. Moreover, the study demonstrated the value of rtGS in revealing secondary findings (SFs) and VUSs. SFs not only provide insights into potential health risks for the neonates undergoing genome sequencing, but also yield benefits for their immediate and extended family members, such as siblings, parents, and grandparents. 2 On the basis of informed consent, these family members can examine their own carrier status of the SFs through cascade testing, thereby evaluating the potential health risks for themselves. Importantly, the identification of actionable SFs has the potential to prevent severe health outcomes later in life. In addition, the study also shed light on VUSs, interpreting them through pathogenicity prediction models. Managing VUSs remains a complex task, necessitating a delicate balance between the uncertainties in these findings and respect for patient autonomy. 3 The interpretation of VUSs, as demonstrated in this study, consistently contributes to the broader genetic knowledge base, thereby enriching future diagnostic methodologies that potentially evolve from our current understanding of today's VUSs. Despite its clinical value, the primary obstacle to the application of genome sequencing in neonatal care is economic rather than technical. The cost-effectiveness of implementing genome sequencing in neonatal intensive care remains a complex and challenging issue. First, many diseases potentially identifiable in neonates are rare and often lack comprehensive medical strategies for management. This limitation hinders the development of a complete economic model for sequencing, as the downstream implications of numerous health conditions remain uncertain. Second, economic evaluations must consider the vast array of disorders detectable by this technology, necessitating the use of complex and large-scale models that encompass a wide range of conditions. Accurately accounting for the full spectrum of costs and outcomes of these conditions, including those arising from both the upstream and downstream events, such as future medical events, is extremely challenging. 4 Third, while the detection of SFs may improve the cost-effectiveness of genome sequencing for the neonates through cascade testing, it is worth noting that the disclosure of SFs should be on an informed consent basis. Accurately evaluating the impact of SFs on the cost-effectiveness of genome sequencing depends on our ability to ascertain and integrate the preferences of parents (the guardians of the neonates) and physicians (the gatekeepers of SFs) toward the disclosure of neonatal patients' SFs into economic models. Without measuring and incorporating these preference parameters, it becomes challenging to precisely determine the extent to which the inclusion of SFs improves the cost-effectiveness of genome sequencing. 5 Similarly, the detection of VUSs complicates the assessment of cost-effectiveness. Presently, the -Abstract Truncated-
medicine, general & internal